Search results
Showing 241 to 255 of 1373 results for social care
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
In development Reference number: GID-TA10497 Expected publication date: TBC
Recommendation ID NG213/04 Question Care close to home: What are the most effective commissioning, practice and service delivery models
This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.
View quality statements for QS22Show all sections
Sections for QS22
- Quality statements
- Quality statement 1: Access to antenatal care
- Quality statement 2: Risk assessment
- Quality statement 3: Continuity of carer
- Quality statement 4: Vaccination
- Quality statement 5: Referral for stop-smoking support and treatment
- Quality statement 6: Healthy eating in pregnancy
- Update information
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
This guideline covers recognising, assessing and treating bipolar disorder (formerly known as manic depression) in children, young people and adults. The recommendations apply to bipolar I, bipolar II, mixed affective and rapid cycling disorders. It aims to improve access to treatment and quality of life in people with bipolar disorder.
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
In development Reference number: GID-TA11437 Expected publication date: TBC
Suspected neurological conditions: recognition and referral (QS198)
This quality standard covers assessing and referring children (under 16) and adults (16 and over) who have symptoms or signs associated with neurological conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS198Show all sections
Sections for QS198
- Quality statements
- Quality statement 1: Headaches and 'red flag' symptoms in children
- Quality statement 2: Head size and shape in children
- Quality statement 3: Suspected dystonia in adults
- Quality statement 4: Hallpike manoeuvre for adults
- Quality statement 5: Functional neurological disorders in adults
- Quality statement 6: Individualised care for adults
- About this quality standard
This guideline covers assessing and managing food allergy in children and young people under 19. It aims to improve symptoms such as faltering growth and eczema by offering advice on how to identify food allergy and when to refer to secondary or specialist care.
workers for delivering joined-up services to meet the education, health and social care needs of disabled children and young people with...
young people with severe complex needs receive education, health and social care support? Any explanatory notes(if applicable) For a...
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
In development Reference number: GID-TA11669 Expected publication date: 03 September 2026